Annual Long Term Debt
$90.10 K
-$115.40 K-56.16%
31 December 2023
Summary:
Inhibikase Therapeutics annual long term debt is currently $90.10 thousand, with the most recent change of -$115.40 thousand (-56.16%) on 31 December 2023. During the last 3 years, it has fallen by -$186.40 thousand (-67.41%). IKT annual long term debt is now -67.41% below its all-time high of $276.50 thousand, reached on 31 December 2020.IKT Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Debt
$0.00
-$25.60 K-100.00%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly long term debt is currently $0.00, with the most recent change of -$25.60 thousand (-100.00%) on 30 September 2024. Over the past year, it has dropped by -$121.00 thousand (-100.00%). IKT quarterly long term debt is now -100.00% below its all-time high of $675.00 thousand, reached on 30 September 2020.IKT Quarterly Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Long Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.2% | -100.0% |
| 3 y3 years | -67.4% | - |
| 5 y5 years | - | - |
IKT Long Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -67.4% | -100.0% | ||
| 5 y | 5 years | -67.4% | -100.0% | ||
| alltime | all time | -67.4% | -100.0% |
Inhibikase Therapeutics Long Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) |
| June 2024 | - | $25.60 K(-56.1%) |
| Mar 2024 | - | $58.30 K(-35.3%) |
| Dec 2023 | $90.10 K(-56.2%) | $90.10 K(-25.5%) |
| Sept 2023 | - | $121.00 K(-19.3%) |
| June 2023 | - | $150.00 K(-15.8%) |
| Mar 2023 | - | $178.10 K(-13.3%) |
| Dec 2022 | $205.50 K | $205.50 K(-11.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $232.00 K(>+9900.0%) |
| Dec 2021 | $0.00(-100.0%) | $0.00(-100.0%) |
| June 2021 | - | $248.90 K(0.0%) |
| Mar 2021 | - | $248.90 K(-10.0%) |
| Dec 2020 | $276.50 K(+0.4%) | $276.50 K(-59.0%) |
| Sept 2020 | - | $675.00 K(+7.7%) |
| June 2020 | - | $626.80 K(+100.3%) |
| Mar 2020 | - | $312.90 K(+13.6%) |
| Dec 2019 | $275.40 K | $275.40 K |
FAQ
- What is Inhibikase Therapeutics annual long term debt?
- What is the all time high annual long term debt for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual long term debt year-on-year change?
- What is Inhibikase Therapeutics quarterly long term debt?
- What is the all time high quarterly long term debt for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly long term debt year-on-year change?
What is Inhibikase Therapeutics annual long term debt?
The current annual long term debt of IKT is $90.10 K
What is the all time high annual long term debt for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual long term debt is $276.50 K
What is Inhibikase Therapeutics annual long term debt year-on-year change?
Over the past year, IKT annual long term debt has changed by -$115.40 K (-56.16%)
What is Inhibikase Therapeutics quarterly long term debt?
The current quarterly long term debt of IKT is $0.00
What is the all time high quarterly long term debt for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly long term debt is $675.00 K
What is Inhibikase Therapeutics quarterly long term debt year-on-year change?
Over the past year, IKT quarterly long term debt has changed by -$121.00 K (-100.00%)